Skip to main content
رجوع
KYMR logo

Kymera Therapeutics, Inc.

جودة البيانات: 100%
KYMR
NASDAQ Healthcare Biotechnology
KWD 74.42
▼ KWD 2.54 (-3.30%)
القيمة السوقية: 6.08B
نطاق اليوم
KWD 73.31 KWD 76.01
نطاق 52 أسبوعًا
KWD 19.45 KWD 103.00
حجم التداول
596,547
متوسط 50 يوم / 200 يوم
KWD 79.67 / KWD 61.62
الإغلاق السابق
KWD 76.96

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -19.5 0.3
P/B 3.9 2.9
ROE % -25.8 3.7
Net Margin % -794.4 3.8
Rev Growth 5Y % -14.4 10.0
D/E 0.1 0.2

السعر المستهدف للمحللين

Hold
KWD 117.310 +57.6%
Low: KWD 90.000 High: KWD 138.000
ربحية السهم المستقبلية
-KWD 3.662
الإيرادات المقدّرة
40 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 -KWD 3.413
-KWD 9.666 – KWD 0.664
220 M 12
FY2029 -KWD 4.311
-KWD 12.212 – KWD 0.839
54 M 8
FY2028 -KWD 4.098
-KWD 4.991 – -KWD 3.094
43 M 14

النقاط الرئيسية

Revenue declined -14.35% annually over 5 years
Debt/Equity of 0.05 — conservative balance sheet
Negative free cash flow of -234.34M
Capital efficient — spends only 3.70% of revenue on capex

النمو

Revenue Growth (5Y)
-14.35%
Revenue (1Y)-16.72%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-25.79%
ROIC-15.77%
Net Margin-794.39%
Op. Margin-891.33%

الأمان

Debt / Equity
0.05
Current Ratio10.47
Interest Coverage-1403.21

التقييم

P/E Ratio
-19.51
P/B Ratio3.85
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -16.72% Revenue Growth (3Y) -29.38%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -14.35% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 39.20M Net Income (TTM) -311.40M
ROE -25.79% ROA -17.87%
Gross Margin 100.00% Operating Margin -891.33%
Net Margin -794.39% Free Cash Flow (TTM) -234.34M
ROIC -15.77% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.05 Current Ratio 10.47
Interest Coverage -1403.21 Dividend Yield 0.00%
Valuation
P/E Ratio -19.51 P/B Ratio 3.85
P/S Ratio 155.00 PEG Ratio -0.89
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 6.08B Enterprise Value 5.80B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 39.20M 47.07M 78.59M 46.83M 72.83M
Net Income -311.40M -223.86M -146.96M -154.81M -100.22M
EPS (Diluted) -3.69 -2.98 -2.52 -2.87 -2.09
Gross Profit 39.20M 47.07M 78.59M 46.83M 72.83M
Operating Income -349.40M -261.64M -165.53M -161.26M -100.53M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.74B 978.04M 575.76M 603.13M 605.91M
Total Liabilities 163.15M 142.42M 180.79M 112.98M 146.27M
Shareholders' Equity 1.58B 835.62M 394.97M 490.15M 459.64M
Total Debt 82.25M 87.76M 84.67M 17.34M 17.96M
Cash & Equivalents 357.01M 120.26M 109.97M 68.40M 47.98M
Current Assets 871.21M 510.27M 405.32M 419.42M 451.27M
Current Liabilities 83.21M 67.77M 85.69M 71.34M 92.54M